Tyme Technologies: Why Investors Should Be Bullish On The Eagle Partnership [Seeking Alpha]
Eagle Pharmaceuticals, Inc. (EGRX)
Last eagle pharmaceuticals, inc. earnings: 3/2 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.eagleus.com
Company Research
Source: Seeking Alpha
Summary Tyme nologies recently announced strategic partnership with Eagle Pharmaceuticals for SM-88. Tyme will receive a healthy upfront payment and additional milestones. In return, Eagle gets 15% of SM-88's net revenue. I take a look at the company's press release and discuss what I like and what I don't like about the deal. Now with a healthy cash position, Tyme can focus on getting SM-88 through their pivotal trials and get TYME-18 into the clinic. Tyme nologies ( EGRX I intend to review the Eagle partnership details and present what I like and what I don’t like. In addition, point a couple of key catalysts for investors to keep an eye out for in the coming quarters. Background on SM-88 Cancer cells rely on non-essential amino acids such as tyrosine. SM-88 is a modified dysfunctional tyrosine that is absorbed by the cell. Once in the cell, SM-88 interrupts protein synthesis, which will eventually result in the cell’s death. Thus far, SM-88 has exhibited promising safety and effica
Show less
Read more
Impact Snapshot
Event Time:
EGRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EGRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EGRX alerts
High impacting Eagle Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
EGRX
News
- Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration [Yahoo! Finance]Yahoo! Finance
- Eagle Announces Update on Delisting from Nasdaq and SEC DeregistrationGlobeNewswire
- Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial OfficerGlobeNewswire
EGRX
Sec Filings
- 11/19/24 - Form 3
- 11/15/24 - Form 8-K
- 11/14/24 - Form SC
- EGRX's page on the SEC website